iSpecimen Inc.(ISPC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $11.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ISPC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for iSpecimen Inc. (ISPC), a Healthcare sector company. ISPC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $11.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), iSpecimen Inc. reports quarterly revenue of $156.0K, net income of $-2.3M, free cash flow of $-3.4M. Top institutional holders of ISPC by reported 13-F value include GEODE CAPITAL MANAGEMENT,, JANE STREET GROUP,, UBS Group AG, based on the most recent SEC filings. ISPC trades on the Nasdaq exchange and files with the SEC under CIK 1558569. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ISPC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for iSpecimen Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$156.0K
Net Income
Q1 2026
$-2.3M
Free Cash Flow
Q1 2026
$-3.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-79.2% YoYNet Income
+16.1% YoYOperating Income
+29.5% YoYEPS (Diluted)
+87.0% YoYTotal Assets
+1.9% YoYTotal Debt
Op. Cash Flow
+48.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $1.9M -79.2% | $9.3M -6.4% | $9.9M -4.6% | $10.4M +27.1% | $8.2M | — |
| Net Income | $-10.5M +16.1% | $-12.5M -12.6% | $-11.1M -8.3% | $-10.2M -120.2% | $-4.7M | — |
| Operating Income | $-9.0M +29.5% | $-12.7M -14.0% | $-11.2M -9.7% | $-10.2M -323.3% | $-2.4M | — |
| EPS (Diluted) | $-2.28 +87.0% | $-17.58 +28.4% | $-24.55 -2016.4% | $-1.16 +76.7% | $-4.97 | — |
| Total Assets | $9.5M +1.9% | $9.4M -40.9% | $15.8M -35.7% | $24.6M +296.4% | $6.2M | — |
| Total Debt | — | $1.0M | — | — | — | — |
| Operating Cash Flow | $-4.2M +48.7% | $-8.3M -42.3% | $-5.8M +0.2% | $-5.8M -1917.4% | $-288.4K | — |
Get alerted when ISPC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for iSpecimen Inc. including:
Top Institutional Holders of ISPC
GEODE CAPITAL MANAGEMENT, LLC
$49.2K313,098 shJANE STREET GROUP, LLC
$8.7K55,631 shUBS Group AG
$8.4K53,744 shCITADEL ADVISORS LLC
$7.9K50,471 shVANGUARD FIDUCIARY TRUST CO
$4.4K28,170 shStoneX Group Inc.
$3.1K19,710 shTower Research Capital LLC (TRC)
$1.0K6,651 shBlackRock, Inc.
$444.002,827 shVANGUARD CAPITAL MANAGEMENT LLC
$194.001,237 shSBI Securities Co., Ltd.
$3.0019 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $49.2K | 313,098 |
| JANE STREET GROUP, LLC | $8.7K | 55,631 |
| UBS Group AG | $8.4K | 53,744 |
| CITADEL ADVISORS LLC | $7.9K | 50,471 |
| VANGUARD FIDUCIARY TRUST CO | $4.4K | 28,170 |
| StoneX Group Inc. | $3.1K | 19,710 |
| Tower Research Capital LLC (TRC) | $1.0K | 6,651 |
| BlackRock, Inc. | $444.00 | 2,827 |
| VANGUARD CAPITAL MANAGEMENT LLC | $194.00 | 1,237 |
| SBI Securities Co., Ltd. | $3.00 | 19 |
More Healthcare Companies
View all Healthcare →Put ISPC on your watchlist
Track score changes the day iSpecimen Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ISPC a good stock to buy?
13F Pro's AI-powered analysis of iSpecimen Inc. (ISPC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ISPC are available on the ISPC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ISPC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ISPC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of iSpecimen Inc.'s investment landscape.